Key result
ACE inhibitors reduce mortality and morbidity in post-MI patients, while verapamil and diltiazem are beneficial except in those with heart failure without reversible ischemia.
Why the study?
Do ACE inhibitors and calcium antagonists reduce mortality and morbidity in patients after an acute myocardial infarction?
Do ACE inhibitors and calcium antagonists reduce mortality and morbidity in patients after an acute myocardial infarction?
ACE inhibitors and non-dihydropyridine calcium antagonists (verapamil, diltiazem) improve outcomes post-myocardial infarction, whereas nifedipine may be harmful.
Answers are grounded in this paper and cite their sources.
May support ACE inhibitor preference post-MI; leaves open calcium antagonist role in HF subgroups.
AIM: To review the results of recent studies on the use of angiotensin converting enzyme (ACE) inhibitors and calcium antagonists in patients after an acute myocardial infarction. METHOD: Literature review. CONCLUSIONS: ACE inhibition reduces mortality and morbidity and improves quality of life in a cost-effective way, demonstrating increased benefits with increasing risks. Calcium antagonism with verapamil and possibly diltiazem reduces mortality and morbidity, except in patients with congestive heart failure without signs of reversible myocardial ischaemia. Nifedipine may have negative effects. The efficacy of the second-generation dihydropyridines remains to be demonstrated.
No takes yet. Share an insight, caveat, or question.
Stig Persson (1995) conducted a review in Acute myocardial infarction. Angiotensin converting enzyme (ACE) inhibitors and calcium antagonists was evaluated on Mortality and morbidity. ACE inhibitors reduce mortality and morbidity in post-MI patients, while verapamil and diltiazem are beneficial except in those with heart failure without reversible ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: